Session » 3S109: RA – Treatments II: Novel Treatments for RA (927–932)
- 4:30PM-6:00PM
-
Abstract Number: 932
Efficacy and Safety of E6011, an Anti-Fractalkine Monoclonal Antibody, in MTX-IR Patients with Rheumatoid Arthritis
- 4:30PM-6:00PM
-
Abstract Number: 929
Efficacy and Safety of Fenebrutinib, a BTK Inhibitor, Compared to Placebo in Rheumatoid Arthritis Patients with Active Disease Despite TNF Inhibitor Treatment: Randomized, Double Blind, Phase 2 Study
- 4:30PM-6:00PM
-
Abstract Number: 927
Efficacy and Safety of Filgotinib for Patients with Rheumatoid Arthritis Naïve to Methotrexate Therapy: FINCH3 Primary Outcome Results
- 4:30PM-6:00PM
-
Abstract Number: 928
Monotherapy with Upadacitinib in MTX-naïve Patients with Rheumatoid Arthritis: Results at 48 Weeks
- 4:30PM-6:00PM
-
Abstract Number: 930
Neurostimulation for Treatment of Drug Refractory Rheumatoid Arthritis: A First-in-Human Study Using a Novel Vagus Nerve Stimulator
- 4:30PM-6:00PM
-
Abstract Number: 931
Ultra-Low Doses of Rituximab for Retreatment of RA: A Randomized Controlled Non-Inferiority Trial